ArticleFrontiers in veterinary science2026
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: The optimal extraction process of Results: The optimal extraction conditions (80% ethanol, solid-liquid ratio of 1:20, 60 °C for 30 min) yielded a flavonoid content of 10.72%. The crude flavonoid extract exerted a significant concentration-dependent inhibitory effect on protoscoleces, with an inhibition rate of 85.88% at 40 mg/mL for 24 h. The extract severely damaged protoscolex ultrastructure and upregulated Caspase-3 activity by 4.22-fold to induce protoscolex apoptosis. Biosafety evaluation confirmed that 10 mg/mL flavonoids had no obvious host cell toxicity, with a mouse oral LD₅₀ of 1.43 g/kg and no pathological damage in major organs. In vivo results showed that 20 mg/kg flavonoid treatment effectively reduced hepatic cyst numbers and promoted fibrotic repair in mice. Multi-omics analysis identified 50 flavonoid components and 25 differentially expressed proteins enriched in antiviral immune and RNA degradation pathways, and 16 flavonoids with high target-binding affinity were screened. Among them, myricetrin was the only active monomer, and 5 mg/mL myricetrin glycoside treatment significantly reduced liver cyst volume and achieved effective parasite clearance and tissue repair in vivo. Discussion: This study systematically demonstrates the prominent anti-echinococcosis activity and good biosafety of B. javanica flavonoids both in vitro and in vivo. The flavonoids kill E. granulosus protoscoleces by destroying parasite structure and activating apoptotic pathways, and alleviate liver lesions by promoting tissue fibrosis repair. Myricetrin is identified as the core active substance responsible for the anti-parasitic effect. These findings reveal the material basis and potential mechanism of B. javanica against echinococcosis, filling the gap of natural anti-echinococcosis drug research. This work provides a reliable experimental basis for the development of novel safe and efficient anti-echinococcosis natural drugs, and offers a new strategy for the clinical treatment of cystic echinococcosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.